Epidemiology and burden of HPV-related disease

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 47, Issue , 2018, Pages 14-26

  Serrano, Beatriz ^a,b   Brotons, María ^a,b   Bosch, Francesc Xavier ^a,b   Bruni, Laia ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

Author keywords

Attributable fraction; Cancer; Human papillomavirus; Papillomavirus vaccines; Prevention; Time trends

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; DISEASE BURDEN; HEAD AND NECK CANCER; HUMAN; MOUTH INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; AGE DISTRIBUTION; ANUS TUMOR; FEMALE; GLOBAL DISEASE BURDEN; HEAD AND NECK TUMOR; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PENIS TUMOR; STATISTICS AND NUMERICAL DATA; UTERINE CERVIX TUMOR; VIROLOGY;

AGE DISTRIBUTION; ANUS NEOPLASMS; FEMALE; GLOBAL BURDEN OF DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 85031318450     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2017.08.006     Document Type: Review

References (37)

1. IARC, Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents, vol. 100, 2011, International Agency for Research on Cancer, Lyon, France [Internet]. [Cited 2017 July 20]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf.
2. Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:1 (1999 Sep), 12–19, 10.1002/(SICI)1096-9896(199909)189 1<12::AID-PATH431>3.0.CO;2-F.
3. World Health Organization (WHO), Human papillomavirus vaccines WHO position paper. 2017, World Health Organization, Geneva [Internet]. [Cited 2017 July 20]. Available from: http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1.
4. Bouvard, V., Baan, R., Straif, K., et al. A review of human carcinogens–part B: biological agents. Lancet Oncol 10:4 (2009 Apr), 321–322.
5. Khan, M.J., Castle, P.E., Lorincz, A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:14 (2005 Jul 20), 1072–1079, 10.1093/jnci/dji187.
6. Plummer, M., de Martel, C., Vignat, J., et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4:9 (2016 Sep), e609–616, 10.1016/S2214-109X(16)30143-7.
7. de Martel, C., Plummer, M., Vignat, J., et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141:4 (2017 Aug 15), 664–670, 10.1002/ijc.30716.
8. Bruni, L., Barrionuevo-Rosas, L., Albero, G., et al. ICO/IARC information Centre on papillomavirus and cancer (HPV information Centre). Human papillomavirus and related diseases in the world. Summ Rep, 19, April 2017 [Internet]. [Cited 2017 July 20]. Available from: http://www.hpvcentre.net/index.php.
9. Bruni, L., Diaz, M., Castellsagué, X., et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:12 (2010 Dec 15), 1789–1799, 10.1086/657321.
10. Guan, P., Howell-Jones, R., Li, N., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131:10 (2012 Nov 15), 2349–2359, 10.1002/ijc.27485.
11. Giuliano, A.R., Nyitray, A.G., Kreimer, A.R., et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 136:12 (2015 Jun 15), 2752–2760, 10.1002/ijc.29082.
12. Schim van der Loeff, M.F., Mooij, S.H., Richel, O., et al. HPV and anal cancer in HIV-infected individuals: a review. Curr HIV/AIDS Rep 11:3 (2014 Sep), 250–262, 10.1007/s11904-014-0224-x.
13. Kreimer, A.R., Bhatia, R.K., Messeguer, A.L., et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 37:6 (2010 Jun), 386–391, 10.1097/OLQ.0b013e3181c94a3b.
14. Wood, Z.C., Bain, C.J., Smith, D.D., et al. Oral human papillomavirus infection incidence and clearance: a systematic review of the literature. J Gen Virol 98:4 (2017 Apr), 519–526, 10.1099/jgv.0.000727.
15. Gillison, M.L., Broutian, T., Pickard, R.K.L., et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307:7 (2012 Feb 15), 693–703, 10.1001/jama.2012.101.
16. Ervik, M., Lam, F., Ferlay, J., et al. Cancer Today. 2016, International Agency for Research on Cancer, Lyon, France Cancer Today [Internet]. [Cited 2017 July 20]. Available from: http://gco.iarc.fr/today/home.
17. Forman, D., Bray, F., Brewster, D.H., et al. (eds.) Cancer incidence in five Continents, vol. X (electronic version), 2013, IARC, Lyon [Internet]. [Cited 2017 July 20]. Available from: http://ci5.iarc.fr/CI5I-X/Default.aspx.
18. Vaccarella, S., Lortet-Tieulent, J., Plummer, M., et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 49:15 (1990 2013 Oct), 3262–3273, 10.1016/j.ejca.2013.04.024.
19. de Sanjose, S., Quint, W.G., Alemany, L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:11 (2010 Nov), 1048–1056, 10.1016/S1470-2045(10)70230-8.
20. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Dicker, D., Pain, A., et al. The global burden of cancer 2013. JAMA Oncol 1:4 (2015 Jul), 505–527, 10.1001/jamaoncol.2015.0735.
21. Islami, F., Ferlay, J., Lortet-Tieulent, J., et al. International trends in anal cancer incidence rates. Int J Epidemiol 46:3 (2017 Jun 1), 924–938, 10.1093/ije/dyw276.
22. Venuti, A., Paolini, F., HPV detection methods in head and neck cancer. Head Neck Pathol 6:Suppl. 1 (2012 Jul), S63–S74, 10.1007/s12105-012-0372-5.
23. Hartwig, S., St Guily, J.L., Dominiak-Felden, G., et al. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer, 12, 2017, 19, 10.1186/s13027-017-0129-6.
24. de Sanjosé, S., Alemany, L., Ordi, J., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 49:16 (2013 Nov), 3450–3461, 10.1016/j.ejca.2013.06.033.
25. Alemany, L., Saunier, M., Tinoco, L., et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 50:16 (2014 Nov), 2846–2854, 10.1016/j.ejca.2014.07.018.
26. Alemany, L., Saunier, M., Alvarado-Cabrero, I., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 136:1 (2015 Jan 1), 98–107, 10.1002/ijc.28963.
27. Alemany, L., Cubilla, A., Halec, G., et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol 69:5 (2016 May), 953–961, 10.1016/j.eururo.2015.12.007.
28. Castellsagué, X., Alemany, L., Quer, M., et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst, 108(6), 2016 Jan 28, 10.1093/jnci/djv403 djv403.
29. Patel, H., Wagner, M., Singhal, P., et al. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis, 13, 2013 Jan 25, 39, 10.1186/1471-2334-13-39.
30. Buckley, B., Henschke, N., Maayan, N., et al. Anogenital warts: incidence, prevalence, self-reported history and quality of life. 2016, Cochrane Response, London, UK, 18 [Internet]. [Cited 2017 July 20]. Available from: http://www.who.int/immunization/sage/meetings/2016/october/03_Burden_of_anogenital_warts.pdf.
31. Forman, D., de Martel, C., Lacey, C.J., et al. Global burden of human papillomavirus and related diseases. Vaccine 30:Suppl. 5 (2012 Nov 20), F12–F23, 10.1016/j.vaccine.2012.07.055.
32. Garland, S.M., Kjaer, S.K., Muñoz, N., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience. Clin Infect Dis 63:4 (2016 Aug 15), 519–527, 10.1093/cid/ciw354.
33. Schiller, J.T., Castellsagué, X., Garland, S.M., A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:Suppl. 5 (2012 Nov 20), F123–F138, 10.1016/j.vaccine.2012.04.108.
34. Serrano, B., de Sanjosé, S., Tous, S., et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 51:13 (2015 Sep), 1732–1741, 10.1016/j.ejca.2015.06.001.
35. World Heath Organization (WHO), WHO department on immunization, vaccines and biologicals, World Health Organization, Geneva, [Internet]. [Cited 2017 July 20]. Available from: http://www.who.int/immunization/en/.
36. Bruni, L., Diaz, M., Barrionuevo-Rosas, L., et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 4:7 (2016 Jul), e453–463, 10.1016/S2214-109X(16)30099-7.
37. Drolet, M., Bénard, É., Boily, M.-C., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15:5 (2015 May), 565–580, 10.1016/S1473-3099(14)71073-4.